B+
Bull case
25%
Probability
Target price
$1.45
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
CGC
Canopy GrowthBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Primary company disclosure supports a cautious bull case built on improving cannabis revenue mix, MTL integration, lower financing risk, and management's explicit FY2027 positive Adjusted EBITDA goal [#SEC-8K-2026-06-15].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Even after replacing unrelated biotech screen peers with cannabis comparators, peer-level evidence is still thin, which reduces confidence in valuation framing and makes the stock more sensitive to each quarterly proof point.
Momentum
92
Value
41
Sentiment
76
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.10 · Bull $1.45 · Bear $0.60Analysis 2026-06-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-18
Investment thesis
As of 2026-09-18
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-18. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $1.58
Why
Momentum92 · Δ7d -
Value41 · Δ7d 0.0
Sentiment76 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Even after replacing unrelated biotech screen peers with cannabis comparators, peer-level evidence is still thin, which reduces confidence in valuation framing and makes the stock more sensitive to each quarterly proof point.
- • Execution risk around integrating MTL Cannabis remains material because management's medium-term margin and EBITDA case depends on realizing synergies and operational improvements [#SEC-8K-2026-06-15].
- • The bear case is that revenue growth still has not translated into durable reported profitability, and low-coverage follow-through leaves limited external confirmation that the FY2027 EBITDA path is achievable; secondary earnings commentary also indicated revenue and EPS missed consensus, reinforcing execution risk [#PR-EARNINGS-2026-06-16].
Catalyst clock
2026-09-30
Next few quarters need to convert medical and international growth into cleaner reported margins
Lead driver: Sentiment · See AI snapshot
Momentum
92
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.0
Sentiment
76
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 92.2 / Value 41.2 / Sentiment 75.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-25. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.10
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.60
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$446.94M
Beta
0.57
Shares Out
423.04M
P/E (TTM) · Derived
-1.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.15
Rev YoY
+12.5%
EPS YoY
-85.5%
Gross Margin
+18.2%
Op Margin
-25.4%
Net Debt
-$65.22M
Current Ratio
3.04
As of 2026-09-18 • Updated nightlySource: Internal modelMethods & Data